-
October 01 2022 -
June 01 2022 -
May 18 2022 -
November 05 2021 -
October 28 2020 -
October 21 2020 -
March 26 2020
-
March 03 2020 -
DxTerity Names Brett Swansiger Chief Commercial Officer February 3, 2020
Eyes Clinical Adoption of IFN-1 and MIP testing
LOS ANGELES, CA – January 6, 2019 – DxTerity Diagnostics Inc. has announced the hiring of Brett Swansiger for the position of CCO – Chief Commercialization Officer. As Chief Commercial Officer and SVP of Managed Care, Brett will be responsible for [...]
| DxTerity® Launches Interferon Test for Lupus |
|
November 8, 2019
LabPulse also featured the news this morning, as scheduled:
November 8, 2019 -- California-based genomics company DxTerity is releasing data showing the association between type 1 interferon (IFN-1 [...]
| DxTerity® Brings Precision Medicine to Systemic Lupus Erythematosus (SLE) |
|
November 8, 2019
DxTerity® Brings Precision Medicine to Systemic Lupus Erythematosus (SLE)
Along with the release of new Longitudinal SLE Clinical Study Results, the diagnostics company announces the commercial launch of DxTerity Type-1 Interferon Testing
< [...]
| DxTerity Inks Updated Thermo Fisher Licensing Deal |
|
November 8, 2019
Eyes global delivery of Modular Immune Profile (MIP) Assay for Autoimmune Disease
LOS ANGELES, CA – November 8, 2019 – DxTerity Diagnostics Inc. has announced the signing of a multi-year licensing and supply agreement with Thermo Fisher Scientific. Under the terms of the agr [...]
| DxTerity Diagnostics IFN-1 Test |
|
October 29, 2019
Genome Web
DxTerity Diagnostics has launched the IFN-1 Test for determining a systemic lupus erythematosus patient's type 1 interferon status and the risk of progressing to lupus nephritis. The firm launched the test after releasing results of a lon [...]